History of prostate cancer: Diagnosis and treatment timeline - 1904 to 2012

 BERKELEY, CA (UroToday.com) -
1904 Radical perineal prostatectomy (Hugh Hampton Young)
1913 Direct implantation of radium into prostate
1936 Elevated acid phosphatase in PCa (Ethel and Alexander Gutman)
1941 Beneficial effects of castration and estrogen in men with advanced PCa (Charles Huggins)
1947 Retropubic radical prostatectomy (Terrence Millin)
1962 Megavoltage radiation for localized PCa (Malcolm Bagshaw)
1966 Gleason scoring developed
1973 National Veterans study reports benefits of hormonal therapy
1975 First RTC using chemotherapy in prostate cancer (W.W. Scott, et al.)
1980 PSA found elevated in serum of men with prostate cancer
1981 LHRH analogues first used          
1983 Nerve-sparing prostatectomy preserves erectile function (Patrick Walsh)
Transperineal implantation of radioactive seeds (H. Holms)
1985 FDA approves Leuprolide® to treat PCa
1986 FDA approves PSA to monitor PCa
1987 Researchers identify new specific sub-set of prostate tumors (neuroendocrine, also called small-cell tumors that grow and react to treatment differently than to the common form of PCa adenocarcinomas)
1988 Ultrasound guided biopsy device approved
1989 FDA approves  antiandrogen flutamide
1990 Watchful waiting (active surveillance) introduced to avoid unnecessary radical treatments 3-D conformal radiation therapy developed
1994 FDA approves PSA for screening to detect early PCa
1995 Meta-analysis trial of androgen blockade concludes no significant benefit from combining these drugs
1996 FDA approves anthracenedione Novantrone® to treat advanced prostate cancers that do not respond to hormone therapy
1997 Combination of radiation and hormone therapy to improve PCa survival become standard
2003 Two large clinical trials report Proscar® and Avodart® reduce the risk of developing prostate cancer by up to 25 percent
2004 FDA approves antimicrotubule agent Taxotere® for hard-to-treat prostate cancers
2008 FDA approves CellSearch®, a test for predicting survival and monitoring the impact of treatment for men with advanced prostate cancer
2009 Radiation after surgery or hormone therapy improves survival
Clinical trial reports adjuvant radiation reduces risk PCa will spread 
FDA approves autologous celluar immunotherapy Provenge® for advanced prostate cancer
FDA approves  anti-microtubule agent Jevtana® given with prednisone for advanced prostate cancer that progressed despite prior hormone therapy and chemotherapy with docetaxel
2011 FDA approves the anti-androgen Zytiga® in combination with prednisone for treatment of advanced prostate cancers whose disease progresses despite prior hormone therapy and standard chemotherapy with docetaxel
2012 FDA approves anti-androgen Xtandi® for late stage cancer